Some of the most closely watched results at the American Society of Clinical Oncology (ASCO) meeting this year are those from Chinese firm Shanghai Junshi Biosciences Co., Ltd. and its partner Coherus BioSciences, Inc. for the anti-PD-1 antibody toripalimab in first-line nasopharyngeal carcinoma (NPC).
Toripalimab Set For ASCO Buzz With New Nasopharyngeal Data
First-Line PFS Improvements
Junshi and Coherus's PD-1 was already gaining attention for a particularly difficult cancer type even before the meeting, but new data add to its luster ahead of a potential US approval.
